277 related articles for article (PubMed ID: 30043247)
1. Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.
La Foresta S; Faraone C; Sframeli M; Vita GL; Russo M; Profazio C; Rulli I; Gitto E; Versaci A; Messina S; Vita G
Neurol Sci; 2018 Nov; 39(11):1961-1964. PubMed ID: 30043247
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
3. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive institutional overview of intrathecal nusinersen injections for spinal muscular atrophy.
Mousa MA; Aria DJ; Schaefer CM; Kaye RD; Abruzzo TA; Bernes SM; Willard SD; Riemann MC; Towbin RB
Pediatr Radiol; 2018 Nov; 48(12):1797-1805. PubMed ID: 30022258
[TBL] [Abstract][Full Text] [Related]
5. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients.
Wurster CD; Winter B; Wollinsky K; Ludolph AC; Uzelac Z; Witzel S; Schocke M; Schneider R; Kocak T
J Neurol; 2019 Jan; 266(1):183-194. PubMed ID: 30460449
[TBL] [Abstract][Full Text] [Related]
7. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
Yong J; Moffett M; Lucas S
J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
[TBL] [Abstract][Full Text] [Related]
8. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
[TBL] [Abstract][Full Text] [Related]
9. Nusinersen for SMA: expanded access programme.
Farrar MA; Teoh HL; Carey KA; Cairns A; Forbes R; Herbert K; Holland S; Jones KJ; Menezes MP; Morrison M; Munro K; Villano D; Webster R; Woodcock IR; Yiu EM; Sampaio H; Ryan MM
J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):937-942. PubMed ID: 29549190
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
11. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
12. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-guided cervical puncture for nusinersen administration in adolescents.
Ortiz CB; Kukreja KU; Lotze TE; Chau A
Pediatr Radiol; 2019 Jan; 49(1):136-140. PubMed ID: 30167764
[TBL] [Abstract][Full Text] [Related]
14. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal delivery of nusinersen in individuals with complicated spines.
Cartwright MS; Ward ZT; White EP; West TG
Muscle Nerve; 2020 Jul; 62(1):114-118. PubMed ID: 32319101
[TBL] [Abstract][Full Text] [Related]
16. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
17. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
18. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
19. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
[TBL] [Abstract][Full Text] [Related]
20. Outcomes in type 1 spinal muscular atrophy on nusinersen: A single center experience.
Kaltman J; Kern-Smith E; Zhang C; Figueroa J; Ritchey M; Razdan R; Verma S
Clin Neurophysiol; 2020 Dec; 131(12):2793-2794. PubMed ID: 33130439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
